Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors

Cancer Research

Volumn 56, Issue 17, 1996, Pages 3998-4005

  Elliott, P J ^a   Hayward, N J ^a   Dean, R L ^a   Blunt, D G ^a   Bartus, R T ^a,b  

^a ALKERMES INC   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE 5' (N ETHYLCARBOXAMIDE); ANTINEOPLASTIC AGENT; BRADYKININ RECEPTOR AGONIST; CARBON 14; CARBOPLATIN; HISTAMINE; LOBRADIMIL;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG UPTAKE; FEMALE; GLIOMA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTORADIOGRAPHY; BLOOD-BRAIN BARRIER; BRADYKININ; BRAIN; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CARBON RADIOISOTOPES; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; GLIOMA; HISTAMINE; HYPOTENSION; RATS; RATS, WISTAR;

EID: 0029819682     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Curran, W J., Scott, C. B., Horton, J., Nelson, J S., Weinstein, A. S., Fischbach, A. J , Chang, C H., Rotman, M , Asbell, S. O , Kirsch, R. E., and Nelson, D. F. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials J. Natl. Cancer Inst., 85: 704-710, 1993
2. Hiesiger, E M , Green, S. B., Shapiro, W. R., Burger, P. C , Selker, R. G., Mahaley, M. S., Jr., Ransohoff, J., II, Van Gilder, J. C., Mealey, J , Jr., Robertson, J. T , Hochberg, F. H. and Young, R. F. Results of a randomized trial comparing intraarterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults brain tumor cooperative group trial 8420A. J. Neuro-Oncol, 25: 143-154, 1995.
3. Nelson, D. F., McDonald, J. V , Lapham, L. W., Qazi, R., and Rubin, P. Central nervous system tumors. In. R. Rubin, S McDonald, and R Qazi (eds.), Clinical Oncology, pp. 617-644 Philadelphia W. B. Saunders Co , 1992
4. Long, D. M. Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg , 32, 127-144, 1970.
5. Groothuis, D. R , Fischer, J. R., Lapin, G , Bigner, D. D , and Vick, N. A Permeability of different experimental brain tumor models to horseradish peroxidase J Neuropathol. Exp. Neurol., 41: 164-185, 1982.
6. Neuwelt, E A., Barnett, P A., Bigner, D. D., and Frenkel, E. P Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc. Natl Acad Sci USA, 79 4420-4423, 1982.
7. Shibata, S Ultrastructure of capillary walls in human brain tumors Acta Neuropathol., 78: 561-571, 1989
8. Levin, V. A , Freeman-Dove, M , and Landahl, H D. Permeability characteristics of brain adjacent to tumors in rats. Arch. Neurol., 32: 785-791, 1975.
9. 14C-MTX) delivery by intravenous vs intracaiotid (IC) route without or with IC mannitol in experimental rat brain tumors as measured by quantitative autoradiography (QAR). Proc. Am. Assoc. Cancer, 25: 363, 1984
10. Shapiro, W. R., and Shapiro, J R. Principles of brain tumor chemotherapy. Semin Oncol., 13: 56-69, 1986.
11. Shapiro, W. R., Green, S. B., Burger, P. C. Selker, R. G. VanGilder, J C., Roberton, J T , Mealey, J , Ransohoff, J., and Mahaley, M. S A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant gliomas. J Neurosurg , 76: 772-781, 1992
12. Warnick, R E , Prados, M. D., Mack, E. E., Chandler, K. L., Doz, F., Rabbitt, J E., and Malec, M K. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J. Neuro-Oncol , 19: 69-74, 1994.
13. Larner, J. M , Phillips, C D , Dion, J. E , Jensen, M. E, Newman, S. A., and Jane, J A A phase 1-2 trial of superselective carboplatin, low-dose infusional 5-fluorouracil and concurrent radiation for high grade gliomas. Am. J. Clin Oncol., 18: 1-7, 1995.
14. Tomiwa, K., Hazama, F , and Mikawa, H. Neurotoxicity of vincristine after osmotic opening of the blood-brain barrier. Neuropathol. Appl. Neurobiol., 9: 345-354, 1983
15. Neuwelt, E. A., Hill, S. A , and Frenkel, E. P Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening. Neurosurgery, 15: 362-366, 1984.
16. Neuwelt, E A., and Rapoport, S. I. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed. Proc., 43: 214-219, 1984
17. Neuwelt, E. A., Barnett, P A., McCormick, C. I., Frenkel, E. P , and Minna, J D. Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. Neurosurgery, 17: 419-423, 1985.
18. Nakagawa, H., Groothuis, D., and Blasberg, R. G. The effect of graded hypertonic intracarotid infusions on drug delivery to experimental RG-2 gliomas. Neurology, 34: 1571-1581, 1984.
19. Hiesiger, E M , Voorhies, R. M., Basler, G. A., Lipschutz, L., Posner, J. B., and Shapiro, W R. Opening the blood-brain and blood-tumor barriers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann Neurol., 19: 50-59, 1986.
20. Fishman, R. A. Is there a therapeutic role for osmotic breaching of the blood-brain barrier (Editorial)? Ann. Neurol., 2: 298-299, 1987
21. Inoue, T., Fukui, M, Nishio, S., Kitamura, K , and Nagara, H Hyperosmotic blood-brain barrier disruption in brains of rats with an intracerebrally transplanted RG-C6 tumor. J. Neurosurg., 66: 256-263, 1987.
22. Millay, R. H., Klein, M. L., Shults, W T , Dahlborg, S. A., and Neuwelt, E A Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. Am. J Ophthalmol , 102: 626-632, 1986.
23. Rapoport, S I. Osmotic opening of the blood-brain barrier. Ann. Neurol., 24: 677-689, 1988.
24. Williams, P. C., Henner, W. D., Roman-Goldstein, S., Dahlborg, S. A., Brummett, R. E , Tableman, M , Dana, B. W., and Neuwelt, E. A. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery, 37 17-28, 1995
25. Black, K. L. Biochemical opening of the blood-brain barrier. Adv. Drug Rev., 15: 37-52, 1995.
26. Raymond, J. J., Robertson, D. M., and Dinsdale, H. B. Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier Can. J Physiol. Pharmacol , 13: 214-220, 1986.
27. Inamura, T., and Black, K L. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors J Cereb. Blood Flow Metab , 14: 862-870, 1994.
28. Doctrow, S. R., Abelleira, S. M., Curry, L. A , Heller-Harrison, R , Kozarich, J W, Malfroy, B , McCarroll, L A , Morgan, K G., Morrow, A. R., Musso, G. F , Smart, J L., Sträub, J. A., Turnbull, B , and Gloff, C. A. The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells. J. Pharmacol. Exp. Ther., 271: 229-237, 1994.
29. Straub, J. A , Akiyama, A., and Parmar, P. In vitro plasma metabolism of RMP-7. Pharm Res , 11: 1673-1676, 1994
30. Bartus, R. T., Elliott, P J , Hayward, N. J., Dean, R. L., McEwen, E., and Fisher, S. K. Bradykinin permeation of the BBB: evidence for a sensitive auto-regulated, receptor-mediated system. Immunopharmacology, 33: 270-278, 1996.
31. Sanovich, E , Bartus, R. T , Friden, P. F., Dean, R. L., Le, H Q., and Brightman, M. W Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res., 705: 125-135, 1995
32. Brightman, M. W., and Reese, T. S. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol., 40: 648-677, 1969
33. Brightman, M. W , Hori, M , Rapoport, S. L. Reese, T S., and Westergaard, E Osmotic opening of tight junctions in cerebral endothelium. J. Comp. Neurol., 152: 317-326, 1973.
34. Dorovini-Zis, K., Bowman, P. D , Betz, A. L., and Goldstein, G. W. Hyperosrnotic arabinose solutions open tight junctions between brain capillary endothelial cells m tissue culture Brain Res , 302: 383-386, 1984
35. Inamura, T., Nomura, T., Bartus, R T., and Black, K. L Intracarotid infusion of RMP-7, a bradykinin analog, a method for selective drug delivery to brain tumors. J. Neurosurg., 81 752-758, 1994.
36. Nomura, T., Inamura, T., and Black, K L Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors Brain Res , 659, 62-66, 1994
37. Matsukado, K., Inamura, T., Nakano, S., Fukui, M , Bartus, R. T., and Black, K L Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusions of bradykinin analog, RMP-7 Neurosurgery, in press, 1996.
38. Bartus, R. T., Elliott, P. J., Dean, R. L., Hayward, N J., Nagle, T L., Huff, M. R , Snodgrass, P A., and Blunt, D. G. Controlled modulation of BBB permeability using the bradykinin agonist. RMP-7. Exp Neurol , in press, 1996.
39. DeVita, V. T. Principles of chemotherapy. In: V. T DeVita, S Hellman, and S. A, (eds.), Cancer, Principles & Practice of Oncology, pp 276-292 Philadelphia: J. B. Lippincott Company, 1993
40. Levin, V. A., Wara, W. M , Davis, R. L , Vestnys, P., Resser, K. J , Yatsko, K , Nutik, S , Gutin, P H., and Wilson, C. B. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J. Neurosurg., 63: 218-223, 1985.
41. Levin, V. A., Silver, P., Hannigan, J., Wara, W. M., Gutin, P H., Davis, R. L , and Wilson, C. B Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J. Radiat. Oncol. Biol. Phys , 18: 321-324, 1990.
42. Rozencweig, M , von Hoff, D. D , Slavik, M., and Muggia, F. M. cis-diamminedichloroplatinum(II). A new anti-cancer drug. Ann. Intern. Med , 86: 803-812, 1977.
43. Stewart, D J., Benjamin, R. S., Zimmerman, S., Capriolli, R. M , Wallace, S., Chuang, V., Calvo, D., Samuels, M., Bonura, J , and Loo, T. L. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II) Cancer Res., 43: 917-920, 1983
44. Walker, R. W., Dantis, E., and Shapiro, W. R Treatment of recurrent glioma with carboplatin Proc. Am. Soc. Clin. Oncol. Annu. Meet., 6 272, 1987.
45. Poisson, M., Pereon, Y., Chiras, J., and Delattre, J Y. Treatment of recurrent malignant supratentorial gliomas with carbopiatin (CBDCA) J Neuro-Oncol., 10: 139-144, 1991.
46. Yung, W. K., Mechtler, L., and Gleason, M J Intravenous carboplatin for recurrent malignant glioma: a phase II study J. Clin Oncol., 9: 860-864, 1991.
47. Chandler, K. L , and Prados, M. D. Chemotherapy of brain tumors: clinical aspects. In: R. A. Morantz and J. W. Walsh (eds ), Brain Tumors A Comprehensive Text, pp. 731-744. New York. Marcel Dekker, Inc., 1994.
48. Gumerlock, M. K., and Neuweit, E. A. Chemotherapy of brain tumors: innovative approaches In. R. A. Morantz and J. W. Walsh (eds.), Brain Tumors A Comprehensive Text, pp. 763-778. New York: Marcel Dekker, Inc , 1994.
49. Wilkinson, R., Cox, P. J., Jones, M., and Harrap, K. R Selection of potential second generation platinum compounds. Biochemie, 60: 851-857, 1978
50. Bradner, W. R., Rose, W. C., and Huftalen, J B. Anti-tumor activity in platinum analogs In A. W. Prestayko, S. T Crooke, and S. K. Carter, Cisplatin - Current Status and New Development, pp. 171-182. New York. Academic Press, 1980.
51. Lelieveld, P., Van Der Vijgh, W. J. F., Veldhuizen, W , Van Velzen, D., Van Putten, L. M , Atassi, G. and Danguy, A Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives. Eur. J. Cancer Clin. Oncol., 20: 1087-1104, 1984.
52. von Hoff, D. D , Schilzky, R., Reichert, C. M., Reddick, R. L., Rozencweig, M., Young, R. C , and Muggia, F. M. Toxic effects of cis-dichlorodiammineplatinun(II) in man Cancer Treat. Rep., 63: 1527-1531, 1979.
53. Maiese K., Walker, R. W., Gargan, R., and Victor, J. D. Intra-artenal cisplatin-associated optic and otic toxicity. Arch. Neurol., 49: 83-86, 1992
54. Patel, M , Godwin, K., McCully, C., Adamson, P., and Balis, F Plasma and cerebrospinal fluid pharmacokinetics of carboplatin and cisplatin Proc. Am. Assoc. Cancer Res., 367: 403-404, 1996.
55. Pellegrino, L J., Pellegrino, A. S., and Cushman, A. J. A Stereotaxic Alias of the Rat Brain, 2nd ed. New York: Plenum Press, 1986
56. Kessler, M J. Liquid scintillation analysis. Packard Publ. 169-3052, 1989.
57. Ohno, K., Pettigrew, K. O., and Rapoport, S. I. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol , 253 H299-H307, 1978.
58. Ziylan, Y. Z., LeFauconnier, J. M., Bernard, G., and Bourre, J M. Effect of dexamethasone on transport of alpha-aminoisobutyric acid and sucrose across the blood-brain barrier J. Neurochem., 51: 1338-1342, 1988
59. Haddy, F. J., Emerson, T. E , Scott, J B , and Daugherty, R. M The effect of the kinins on the cardiovascular system. Handb Exp Pharmacol , 25: 362-384, 1970.
60. Donelli, M. G , Zucchetti, M., and D'Incalci, M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother. Pharmacol , 30: 251-260, 1992.
61. Hochberg, F. A., and Pruit, A. Assumptions from the radiotherapy of glioblastoma. Neurology, 30: 907-911, 1980.
62. Walner, K E , Galichih, J. H , Krol, G., Aribit, E., and Malkin, N. G Patterns of failure following treatment of glioblastoma multiforme and anaplastic astrocytoma. Int. J Radiat. Biol. Oncol. Phys., 16: 1405-1409, 1989.
63. Lesser, G. J , and Grossman, S. The chemotherapy of high-grade astrocytomas. Semin. Oncol., 21: 220-235, 1994.
64. Canetta, R., Bragman, K., Smaldone, L., and Rozencweig, M. Carboplatin: current status and future prospects. Cancer Treat. Rev., 15 (Suppl. B): 17-32, 1988.
65. Stewart, D J , Belanger, J. M. E. G., Grahovac, Z , Curuvija, S., Gionet, L. R., Aitken, S E., Hugenholtz, H., Benoit B G., and DaSilva, V. F. Phase I study of intracarotid administration of carboplatin. Neurosurgery, 30: 512-517, 1992
66. Elliott, P. J., Hayward, N. J , Huff, M R , Nagle, T. L., Black, K. L., and Battus, R. T. Unlocking the blood brain barrier: a role for RMP-7 in brain tumor therapy, in press, 1996.
67. Elliott, P. J., Hayward, N. J., Dean, R. L., and Bartus, R. T. Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7. Immunopharmacology, 33: 205-208, 1996.
68. Garrison, J. C., and Rall, T. W. Autocoids; drug therapy of inflammation. In: A. G. Gilman, T W. Rall, A. S. Nies, and P. Taylor (eds.), The Pharmacological Basis of Therapeutics, pp 574-599 New York: Pergamon Press, 1990.
69. Dux, E , and Joo, F Effects of histamine on brain capillaries. Exp. Brain Res., 47: 252-258, 1982
70. Inamura, T , Nomura, T., Ikezaki, K , Fukui, M., Pollinger, G , and Black, K. L. Intracarotid histamine infusion increases blood tumor permeability in RG2 glioma Neurol Res., 16: 125-128, 1994
71. Schilling, L., and Wahl, M. Opening of the blood-brain barrier during cortical supervision with histamine. Brain Res., 653: 289-296, 1994.
72. Johnson, A R., and Erdos, E G. Release of histamine from mast cells by vasoactive peptides. Proc Soc. Exp. Biol. Med., 142: 1252-1256, 1973
73. Devillier, O., Renoux, M., Drapeau, G., and Regoli, R. Histamine release from rat peritoneal mast cells by kinin antagonists Eur. J Pharmacol., 149: 137-140, 1988